Document is current
Any future updates will be listed below
-
Authors
Hegde, Meenakshi http://orcid.org/0000-0002-7778-7871
Joseph, Sujith K.
Pashankar, Farzana http://orcid.org/0000-0003-2883-0957
DeRenzo, Christopher
Sanber, Khaled
Navai, Shoba http://orcid.org/0000-0003-1220-2788
Byrd, Tiara T.
Hicks, John
Xu, Mina L.
Gerken, Claudia
Kalra, Mamta
Robertson, Catherine
Zhang, Huimin
Shree, Ankita
Mehta, Birju
Dakhova, Olga
Salsman, Vita S.
Grilley, Bambi
Gee, Adrian
Dotti, Gianpietro
Heslop, Helen E.
Brenner, Malcolm K.
Wels, Winfried S.
Gottschalk, Stephen http://orcid.org/0000-0003-3991-7468
Ahmed, Nabil http://orcid.org/0000-0002-0982-8424
-
Funding
Funding for this research was provided by:
EIF | Stand Up To Cancer (SU2C-AACR-DT1113)
American Association for Cancer Research (SU2C-AACR-DT1113)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1U54CA232568-01, K12CA090433)
Alex's Lemonade Stand Foundation for Childhood Cancer
Cancer Prevention and Research Institute of Texas (RP101335, RP160283)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 28 May 2019
Accepted: 13 June 2020
First Online: 15 July 2020
Competing interests
: M.H., S.K.J., T.T.B., and V.S.S. are named inventors on patent applications in the field of CAR T-cell therapy owned by Baylor College of Medicine (BCM). B.G. owns QBRegulatory Consultants, LLC (QBR) which provides clinical research regulatory and project management support to companies inclusive of Allovir, TESSA therapeutics, Marker Therapeutics Inc, and LOKON Pharma AB. H.E.H. reports ownership equity in Marker Therapeutics and Allovir, consulting with Tessa Therapeutics, Kiadis, Novartis, Gilead Biosciences, PACT Pharma, Marker Therapeutics, and Allovir, and research grants from Tessa Therapeutics and Cell Medica, outside the submitted work. M.K.B. reports ownership equity in Marker Therapeutics, Tessa Therapeutics, and Allovir, consulting with Tessa Therapeutics, Walking Fish Therapeutic, Memgen, TScan, Allogene, Marker Therapeutics, and Allovir, outside the submitted work. W.S.W. is named as an inventor on patents and patent applications in the field of cancer immunotherapy owned by Georg-Speyer-Haus. S.G. has patent applications in the fields of T-cell and/or gene therapy for cancer and a research collaboration with TESSA Therapeutics, is a DSMB member of Immatics, and on the scientific advisory board of Tidal. N.A. is named inventor on patents and patent applications owned by Baylor College of Medicine. N.A. received one-time royalties from Celgene and Cell Medica, consulted in the past for Adaptimmune and continues to consult for Equillium (pro bono) and The Children’s Cancer Hospital Egypt 57357 on medical education and research development. None of these relationships conflict with the published work. The remaining authors declare no competing financial interests.
